{"id":"ornithine","rwe":[{"pmid":"41904136","year":"2026","title":"Structural basis for pH-responsive amino acid transport via SLC7A4.","finding":"","journal":"Nature communications","studyType":"Clinical Study"},{"pmid":"41892305","year":"2026","title":"Role of Aspartate in Immune Response and Mortality in a Polymicrobial Sepsis Model: Insights from Metabolomics and Transcriptomics.","finding":"","journal":"Cells","studyType":"Clinical Study"},{"pmid":"41887919","year":"2026","title":"Current Insight into Human Ornithine Aminotransferase: A Review.","finding":"","journal":"Proteins","studyType":"Clinical Study"},{"pmid":"41880479","year":"2026","title":"Side Chain Length in Lysine and Its Homologues Modulates Noncovalent Interactions in Histidine-Rich Peptides.","finding":"","journal":"The journal of physical chemistry. B","studyType":"Clinical Study"},{"pmid":"41878007","year":"2026","title":"Genetic constraints on protein loop evolution: out-of-frame stop codons limit Bacillus subtilis stationary-phase mutagenesis.","finding":"","journal":"Frontiers in molecular biosciences","studyType":"Clinical Study"}],"_fda":{"id":"6cb92469-3c55-47e3-9c13-f4b373e2883c","set_id":"0df7e08c-c17f-4e5e-acfd-05f8af7277cc","openfda":{"nui":["M0003493","N0000175903"],"upc":["0649818030825"],"unii":["94ZLA3W45F","7THJ3EG9SY","0G389FZZ9M","E524N2IXA3","19F5HK2737"],"route":["ORAL"],"spl_id":["6cb92469-3c55-47e3-9c13-f4b373e2883c"],"brand_name":["A L O Formula"],"spl_set_id":["0df7e08c-c17f-4e5e-acfd-05f8af7277cc"],"package_ndc":["83027-0084-1"],"product_ndc":["83027-0084"],"generic_name":["CHOLINUM, L-ARGININE, L-CARNITINE, L-ORNITHINE, PANTOTHENIC ACID"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Carnitine [CS]"],"substance_name":["ARGININE","CHOLINE HYDROXIDE","LEVOCARNITINE","ORNITHINE","PANTOTHENIC ACID"],"pharm_class_epc":["Carnitine Analog [EPC]"],"manufacturer_name":["Nutritional Specialties, Inc."],"is_original_packager":[true]},"purpose":["PURPOSE: Aids in mobilization of fat deposits and cellulite.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"version":"1","warnings":["WARNINGS: Professional Use Only If pregnant or breast-feeding, ask a health professional before use. In case of overdose, get medical help or contact a Poison Control Center right away. If condition worsens, seek medical attention. KEEP OUT OF REACH OF CHILDREN Do not use if tamper evident seal is broken or missing. Store in a cool place after opening"],"questions":["QUESTIONS: MANUFACTURED EXCLUSIVELY FOR NUTRITIONAL SPECIALTIES, INC. PO BOX 97227 PITTSBURG, PA 15229 www.phpltd.com"],"effective_time":"20230707","active_ingredient":["ACTIVE INGREDIENTS: Cholinum 6X, 12X, 30X, L-arginine 6X, 12X, 30X, L-Carnitine 6X, 12X, 30X, L-Ornithine 6X, 12X, 30X, Pantothenic Acid 6X, 12X, 30X."],"inactive_ingredient":["INACTIVE INGREDIENTS: Alcohol USP 20%, Purified Water USP."],"indications_and_usage":["INDICATIONS: Aids in mobilization of fat deposits and cellulite.† †Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"dosage_and_administration":["DIRECTIONS: Adults: 2 to 3 sprays orally, three times daily. Children under twelve one half adult dosage. Do not take within 15 minutes of consuming food, beverage or brushing teeth. Consult a physician for use in children under 12 years of age."],"spl_product_data_elements":["A L O Formula Cholinum, L-arginine, L-Carnitine, L-Ornithine, Pantothenic Acid CHOLINE HYDROXIDE CHOLINE ARGININE ARGININE LEVOCARNITINE LEVOCARNITINE ORNITHINE ORNITHINE PANTOTHENIC ACID PANTOTHENIC ACID WATER ALCOHOL"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN: In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["PACKAGE LABEL DISPLAY: METHYLGENETIC NUTRITION HOMEOPATHIC NDC 83027-0084-1 A-L-O FORMULA 2 FL. OZ. (60ml) A-L-O FORMULA"]},"tags":[{"label":"ornithine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"G-protein coupled receptor family C group 6 member A","category":"target"},{"label":"GPRC6A","category":"gene"},{"label":"Active","category":"status"},{"label":"Female Facial Hirsutism","category":"indication"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1 reports"}],"contraindications":["Eruption of skin","Skin irritation"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ORNITHINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:07:56.157729+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:08:02.141346+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ORNITHINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:08:02.514519+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:54.898687+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:54.898710+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:54.898714+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:08:04.605477+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL446143/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:08:03.435295+00:00"}},"allNames":"l-ornithine","offLabel":[],"synonyms":["ornithine","L-Ornithine","(S)-2,5-Diaminopentanoic acid","(S)-Ornithine"],"timeline":[],"approvals":[],"brandName":"L-Ornithine","ecosystem":[{"indication":"Female Facial Hirsutism","otherDrugs":[{"name":"eflornithine","slug":"eflornithine","company":""}],"globalPrevalence":null}],"mechanism":{"target":"G-protein coupled receptor family C group 6 member A","targets":[{"gene":"GPRC6A","source":"DrugCentral","target":"G-protein coupled receptor family C group 6 member A","protein":"G-protein coupled receptor family C group 6 member A"}],"modality":"Small Molecule","drugClass":"Carnitine Analog [EPC]","explanation":"","oneSentence":"","technicalDetail":"L-Ornithine acts as a selective agonist of the G-protein coupled receptor family C group 6 member A, which is involved in the regulation of hair growth and development."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3401","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ORNITHINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ORNITHINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:09:01.037135","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:05.978000+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"arginine","drugSlug":"arginine","fdaApproval":"1973-02-28","patentStatus":"Unknown","relationship":"same-target"}],"genericName":"ornithine","indications":{"approved":[{"name":"Female Facial Hirsutism","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"arginine","brandName":"arginine","genericName":"arginine","approvalYear":"1973","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05042245","phase":"PHASE4","title":"The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2019-07-23","conditions":["Non-alcoholic Fatty Liver Disease"],"enrollment":237,"completionDate":"2022-12-20"},{"nctId":"NCT07287917","phase":"PHASE1,PHASE2","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Aminex Therapeutics, Inc.","startDate":"2026-01-26","conditions":["Melanoma (Skin Cancer)","HER2-low Hormone Receptor Positive Breast Cancer"],"enrollment":92,"completionDate":"2028-12-29"},{"nctId":"NCT07468136","phase":"PHASE1,PHASE2","title":"Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-04-24","conditions":["Anaplastic Oligodendroglioma","Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4","Diffuse Astrocytoma","Glioblastoma, IDH-Wildtype","Malignant Glioma"],"enrollment":33,"completionDate":"2030-10-25"},{"nctId":"NCT06219174","phase":"PHASE1,PHASE2","title":"Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)","status":"SUSPENDED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-07","conditions":["Non Small Cell Lung Cancer","Lung Cancer"],"enrollment":45,"completionDate":"2029-08"},{"nctId":"NCT04696029","phase":"PHASE2","title":"DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2021-03-29","conditions":["Medulloblastoma"],"enrollment":118,"completionDate":"2029-03"},{"nctId":"NCT06465199","phase":"PHASE1,PHASE2","title":"Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-03-28","conditions":["Atypical Teratoid/Rhabdoid Tumor","Embryonal Tumor With Multilayered Rosettes","Ewing Sarcoma","Diffuse Intrinsic Pontine Glioma","Osteosarcoma","Neuroblastoma"],"enrollment":289,"completionDate":"2035-02"},{"nctId":"NCT03581240","phase":"","title":"An Intermediate Expanded Use Trial of DFMO","status":"AVAILABLE","sponsor":"Giselle Sholler","startDate":"","conditions":["Neuroblastoma","Medulloblastoma","Typical Teratoid Rhabdoid Tumor","Embryonal Tumor With Abundant Neuropil and True Rosettes","Ependymoblastoma","Medulloepithelioma"],"enrollment":0,"completionDate":""},{"nctId":"NCT02559778","phase":"PHASE2","title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2015-09","conditions":["Neuroblastoma"],"enrollment":500,"completionDate":"2035-09"},{"nctId":"NCT03636438","phase":"","title":"Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2018-08-30","conditions":["Ornithine Transcarbamylase (OTC) Deficiency"],"enrollment":11,"completionDate":"2029-12"},{"nctId":"NCT03794349","phase":"PHASE2","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-07-08","conditions":["High Risk Neuroblastoma","Recurrent Neuroblastoma","Refractory Neuroblastoma"],"enrollment":94,"completionDate":"2029-03-31"},{"nctId":"NCT05345171","phase":"PHASE3","title":"Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-10-18","conditions":["OTC Deficiency"],"enrollment":32,"completionDate":"2031-03"},{"nctId":"NCT04301843","phase":"PHASE2","title":"Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2020-09-25","conditions":["Neuroblastoma"],"enrollment":131,"completionDate":"2033-10-01"},{"nctId":"NCT02679144","phase":"PHASE2","title":"Neuroblastoma Maintenance Therapy Trial","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2016-02","conditions":["Neuroblastoma"],"enrollment":441,"completionDate":"2033-02"},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":["Prostate Cancer"],"enrollment":50,"completionDate":"2029-11-30"},{"nctId":"NCT07321912","phase":"PHASE2","title":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-04-01","conditions":["Osteosarcoma","Ewing Sarcoma","Ewing Sarcoma Metastatic"],"enrollment":406,"completionDate":"2036-04-01"},{"nctId":"NCT04091022","phase":"PHASE2","title":"Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-01-18","conditions":["Non-melanoma Skin Cancer"],"enrollment":64,"completionDate":"2025-12-11"},{"nctId":"NCT07117630","phase":"PHASE2","title":"An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-25","conditions":["Breast Cancer"],"enrollment":20,"completionDate":"2027-08"},{"nctId":"NCT06255782","phase":"PHASE1,PHASE2","title":"An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency","status":"RECRUITING","sponsor":"iECURE, Inc.","startDate":"2024-04-08","conditions":["Ornithine Transcarbamylase Deficiency","Ornithine Transcarbamylase Deficiency Disease","Ornithine Carbamoyltransferase Deficiency (Disorder)","Urea Cycle Disorders, Inborn"],"enrollment":8,"completionDate":"2026-09"},{"nctId":"NCT05717153","phase":"EARLY_PHASE1","title":"Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-10-01","conditions":["Diffuse Glioma","Malignant Glioma"],"enrollment":18,"completionDate":"2027-09-15"},{"nctId":"NCT03159390","phase":"NA","title":"Metabolism of Ornithine Phenylacetate","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2015-02-03","conditions":["Healthy"],"enrollment":20,"completionDate":"2015-04-30"},{"nctId":"NCT05526066","phase":"PHASE2","title":"Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810","status":"TERMINATED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2022-10-17","conditions":["Ornithine Transcarbamylase Deficiency","OTC Deficiency","OTCD"],"enrollment":8,"completionDate":"2024-10-31"},{"nctId":"NCT05594563","phase":"PHASE2","title":"TArgeting Type 1 Diabetes Using POLyamines (TADPOL)","status":"RECRUITING","sponsor":"Emily K. Sims","startDate":"2023-03-14","conditions":["Type 1 Diabetes"],"enrollment":70,"completionDate":"2028-05"},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":["Overt Hepatic Encephalopathy"],"enrollment":174,"completionDate":"2027-06-30"},{"nctId":"NCT06976424","phase":"PHASE4","title":"Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female","status":"RECRUITING","sponsor":"Khyber Teaching Hospital","startDate":"2025-07-15","conditions":["Hirsuitism"],"enrollment":122,"completionDate":"2025-12-31"},{"nctId":"NCT05879367","phase":"PHASE1","title":"Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","status":"RECRUITING","sponsor":"Orbus Therapeutics, Inc.","startDate":"2023-07-24","conditions":["Glioblastoma, IDH-wildtype","Glioblastoma","Glioblastoma Multiforme","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","GBM","Astrocytoma","Astrocytoma, IDH-Mutant"],"enrollment":66,"completionDate":"2026-06-30"},{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":["Overt Hepatic Encephalopathy"],"enrollment":252,"completionDate":"2025-04-30"},{"nctId":"NCT06892678","phase":"PHASE1,PHASE2","title":"DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2025-04-07","conditions":["Osteosarcoma Recurrent","Ewing's Tumor Recurrent"],"enrollment":15,"completionDate":"2030-04"},{"nctId":"NCT01349881","phase":"PHASE3","title":"S0820, Adenoma and Second Primary Prevention Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-08-23","conditions":["Colorectal Neoplasms"],"enrollment":354,"completionDate":"2032-02-01"},{"nctId":"NCT06488313","phase":"PHASE2","title":"A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD","status":"RECRUITING","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-11-04","conditions":["OTC Deficiency","Ornithine Transcarbamylase Deficiency","OTCD"],"enrollment":9,"completionDate":"2026-09-01"},{"nctId":"NCT02030964","phase":"PHASE1","title":"N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2014-01-16","conditions":["Neuroblastoma"],"enrollment":30,"completionDate":"2023-12-30"},{"nctId":"NCT05737030","phase":"PHASE4","title":"Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Graz","startDate":"2023-02-06","conditions":["Cirrhosis"],"enrollment":55,"completionDate":"2025-12"},{"nctId":"NCT02780219","phase":"NA","title":"Chronic Obstructive Pulmonary Disorder and Acute Exercise","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2016-02-04","conditions":["Pulmonary Disease, Chronic Obstructive"],"enrollment":57,"completionDate":"2020-03-06"},{"nctId":"NCT06805695","phase":"","title":"Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)","status":"RECRUITING","sponsor":"iECURE, Inc.","startDate":"2024-12-23","conditions":["Ornithine Transcarbamylase Deficiency","Ornithine Transcarbamylase Deficiency Disease","Urea Cycle Disorders, Inborn"],"enrollment":13,"completionDate":"2041-07"},{"nctId":"NCT06801951","phase":"NA","title":"Oral Supplement and Acute Resistance Exercise","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2017-12-11","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":16,"completionDate":"2020-02-27"},{"nctId":"NCT05500508","phase":"PHASE1,PHASE2","title":"Oral AMXT 1501 Dicaprate in Combination With IV DFMO","status":"TERMINATED","sponsor":"Aminex Therapeutics, Inc.","startDate":"2022-11-29","conditions":["Cancer","Solid Tumor","Solid Carcinoma","Advanced Cancer","DIPG Brain Tumor","Ovary Cancer","Breast Cancer","Papillary Thyroid Cancer","Head and Neck Cancer","Gastric Cancer","Nsclc","Mesotheliomas Pleural","Mesothelioma Peritoneum","Esophageal Cancer","Diffuse Midline Glioma, H3 K27M-Mutant","Endometrial Cancer","Cervical Cancer","Melanoma","Colorectal Cancer","Glioma, Malignant"],"enrollment":15,"completionDate":"2024-12-12"},{"nctId":"NCT05539027","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-09-20","conditions":["Hepatic Encephalopathy"],"enrollment":140,"completionDate":"2024-10-31"},{"nctId":"NCT02794428","phase":"PHASE2","title":"Chemoprevention of Gastric Carcinogenesis","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2016-09-19","conditions":["Gastric Cancer","Gastric Intestinal Metaplasia"],"enrollment":91,"completionDate":"2024-07-01"},{"nctId":"NCT01059071","phase":"PHASE1","title":"Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide","status":"COMPLETED","sponsor":"Giselle Sholler","startDate":"2010-02","conditions":["Neuroblastoma"],"enrollment":21,"completionDate":"2015-05"},{"nctId":"NCT02139397","phase":"PHASE1,PHASE2","title":"Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma","status":"COMPLETED","sponsor":"Giselle Sholler","startDate":"2014-06-06","conditions":["Neuroblastoma Recurrent"],"enrollment":16,"completionDate":"2024-01-19"},{"nctId":"NCT02395666","phase":"PHASE2","title":"Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission","status":"COMPLETED","sponsor":"Giselle Sholler","startDate":"2015-03-05","conditions":["Neuroblastoma"],"enrollment":140,"completionDate":"2023-08-24"},{"nctId":"NCT04442347","phase":"PHASE1","title":"Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2020-11-03","conditions":["Ornithine Transcarbamylase Deficiency"],"enrollment":16,"completionDate":"2024-04-30"},{"nctId":"NCT01948427","phase":"","title":"Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)","status":"TERMINATED","sponsor":"Amgen","startDate":"2013-09-25","conditions":["Urea Cycle Disorder"],"enrollment":203,"completionDate":"2020-02-24"},{"nctId":"NCT02935283","phase":"","title":"Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2016-08","conditions":["Urea Cycle Disorders"],"enrollment":56,"completionDate":"2025-12"},{"nctId":"NCT06455267","phase":"NA","title":"Preliminary Clinical Study on the Effect of L-ornithine on the Efficacy of Ustekinumab in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-04-01","conditions":["Mild to Severe Crohns Disease"],"enrollment":50,"completionDate":"2025-09-30"},{"nctId":"NCT01569568","phase":"","title":"Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI","status":"COMPLETED","sponsor":"Andrea Gropman","startDate":"2010-09","conditions":["Ornithine Transcarbamylase Deficiency"],"enrollment":49,"completionDate":"2014-08"},{"nctId":"NCT04602325","phase":"","title":"Systemic Biomarkers of Brain Injury From Hyperammonemia","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2020-07-09","conditions":["Urea Cycle Disorder","Organic Acidemia","Maple Syrup Urine Disease","Glutaric Acidemia I","Fatty Acid Oxidation Disorder","Hypoxic-Ischemic Encephalopathy"],"enrollment":24,"completionDate":"2027-05"},{"nctId":"NCT04403282","phase":"PHASE4","title":"Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial","status":"TERMINATED","sponsor":"Walter Reed National Military Medical Center","startDate":"2020-09-27","conditions":["Pseudofolliculitis Barbae"],"enrollment":9,"completionDate":"2023-06-22"},{"nctId":"NCT05092685","phase":"PHASE1,PHASE2","title":"Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn","status":"RECRUITING","sponsor":"University College, London","startDate":"2023-11-01","conditions":["Ornithine Transcarbamylase Deficiency"],"enrollment":12,"completionDate":"2027-06-30"},{"nctId":"NCT05706714","phase":"","title":"Th1, Th2, Th17 Phenotype in Urea Cycle Disorders","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2021-04-06","conditions":["Urea Cycle Disorder","Lysinuric Protein Intolerance"],"enrollment":65,"completionDate":"2023-09-01"},{"nctId":"NCT05920213","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2023-10","conditions":["Hepatic Encephalopathy Stage 2","Hepatic Encephalopathy Stage 3","Hepatic Encephalopathy Stage 4"],"enrollment":360,"completionDate":"2024-04"},{"nctId":"NCT04909346","phase":"","title":"Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2021-06-23","conditions":["Ornithine Transcarbamylase Deficiency","Wilson Disease","Glycogen Storage Disease Type IA"],"enrollment":51,"completionDate":"2022-11-17"},{"nctId":"NCT03536728","phase":"PHASE1","title":"Oral AMXT 1501 Dicaprate in Combination With DFMO","status":"COMPLETED","sponsor":"Aminex Therapeutics, Inc.","startDate":"2018-06-12","conditions":["Cancer","Solid Tumor","Solid Carcinoma","Advanced Cancer"],"enrollment":56,"completionDate":"2023-04-21"},{"nctId":"NCT05778461","phase":"NA","title":"Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure.","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-03-15","conditions":["Liver Failure, Acute"],"enrollment":32,"completionDate":"2024-10-30"},{"nctId":"NCT02991144","phase":"PHASE1,PHASE2","title":"Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency","status":"COMPLETED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2017-07-31","conditions":["Ornithine Transcarbamylase (OTC) Deficiency"],"enrollment":16,"completionDate":"2021-12-16"},{"nctId":"NCT01345578","phase":"PHASE1","title":"Hepatocyte Transplantation for Liver Based Metabolic Disorders","status":"TERMINATED","sponsor":"Ira Fox","startDate":"2011-03","conditions":["Metabolic Diseases"],"enrollment":5,"completionDate":"2022-03-31"},{"nctId":"NCT03577938","phase":"NA","title":"Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment","status":"COMPLETED","sponsor":"Beijing 302 Hospital","startDate":"2019-01-10","conditions":["Acute on Chronic Liver Failure","Traditional Chinese Medicine","Hepatitis B"],"enrollment":516,"completionDate":"2021-06-30"},{"nctId":"NCT04717453","phase":"","title":"Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2020-10-06","conditions":["Ornithine Transcarbamylase Deficiency"],"enrollment":1,"completionDate":"2021-12-15"},{"nctId":"NCT03933410","phase":"PHASE2","title":"UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder","status":"TERMINATED","sponsor":"Kaleido Biosciences","startDate":"2019-09-17","conditions":["Urea Cycle Disorder"],"enrollment":13,"completionDate":"2021-03-02"},{"nctId":"NCT02796261","phase":"PHASE3","title":"Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients","status":"UNKNOWN","sponsor":"Orbus Therapeutics, Inc.","startDate":"2016-07","conditions":["Anaplastic Astrocytoma","Recurrent Anaplastic Astrocytoma"],"enrollment":343,"completionDate":"2023-06"},{"nctId":"NCT04128462","phase":"PHASE3","title":"MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function","status":"WITHDRAWN","sponsor":"Mallinckrodt","startDate":"2021-11","conditions":["Hepatic Encephalopathy"],"enrollment":0,"completionDate":"2025-07"},{"nctId":"NCT03846843","phase":"PHASE1","title":"OCR002-SP103 - Oral Immediate Release Study","status":"COMPLETED","sponsor":"Ocera Therapeutics, Inc.","startDate":"2016-08-15","conditions":["Cirrhosis"],"enrollment":30,"completionDate":"2017-12-31"},{"nctId":"NCT05042024","phase":"PHASE3","title":"Supplementation With L-ornithine But Not L-arginine Increases Density of CD68+ and CD163+ Macrophages in Periodontitis","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2017-10-20","conditions":["Periodontitis"],"enrollment":75,"completionDate":"2018-11-01"},{"nctId":"NCT01966419","phase":"PHASE2","title":"Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)","status":"COMPLETED","sponsor":"Ocera Therapeutics, Inc.","startDate":"2014-01-07","conditions":["Acute Episode of Overt Hepatic Encephalopathy","Hepatic Encephalopathy"],"enrollment":231,"completionDate":"2016-12-29"},{"nctId":"NCT02384889","phase":"PHASE1","title":"DFMO in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-04","conditions":["Type 1 Diabetes"],"enrollment":41,"completionDate":"2020-01-06"},{"nctId":"NCT03712280","phase":"PHASE2","title":"MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2018-12-01","conditions":["Hepatic Cirrhosis","Hepatic Encephalopathy (HE)"],"enrollment":50,"completionDate":"2020-07-14"},{"nctId":"NCT01634230","phase":"","title":"Emergency Use of OCR-002 in Acute Liver Failure (ALF)","status":"NO_LONGER_AVAILABLE","sponsor":"Ocera Therapeutics, Inc.","startDate":"","conditions":["Acute Liver Failure"],"enrollment":0,"completionDate":""},{"nctId":"NCT01483144","phase":"PHASE3","title":"Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)","status":"COMPLETED","sponsor":"Cancer Prevention Pharmaceuticals, Inc.","startDate":"2013-10","conditions":["Familial Adenomatous Polyposis"],"enrollment":171,"completionDate":"2019-03"},{"nctId":"NCT01041755","phase":"PHASE4","title":"Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Centro Regional para el Estudio de las Enfermedades Digestivas","startDate":"2009-11","conditions":["Hepatic Encephalopathy"],"enrollment":30,"completionDate":"2011-06"},{"nctId":"NCT01599286","phase":"PHASE2","title":"Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia","status":"COMPLETED","sponsor":"Mendel Tuchman","startDate":"2012-09-01","conditions":["Propionic Acidemia, Type I and/or Type II","Methylmalonic Acidemia","Carbamoyl-Phosphate Synthase I Deficiency Disease","Ornithine Carbamoyltransferase Deficiency"],"enrollment":35,"completionDate":"2020-04-30"},{"nctId":"NCT00033371","phase":"PHASE2","title":"Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-12-13","conditions":["Colorectal Cancer","Familial Adenomatous Polyposis"],"enrollment":205,"completionDate":"2009-03-24"},{"nctId":"NCT00740142","phase":"PHASE4","title":"Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2008-09","conditions":["Hepatic Encephalopathy"],"enrollment":35,"completionDate":"2011-10"},{"nctId":"NCT00204789","phase":"PHASE2","title":"Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-07","conditions":["Post-solid Organ Transplant","Skin Neoplasms"],"enrollment":52,"completionDate":"2007-12"},{"nctId":"NCT00005884","phase":"PHASE3","title":"Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"","conditions":["Non-melanomatous Skin Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT02731755","phase":"NA","title":"Phenolic-rich Oats and Artery Improvement","status":"COMPLETED","sponsor":"University of Reading","startDate":"2016-01","conditions":["Healthy"],"enrollment":18,"completionDate":"2016-11"},{"nctId":"NCT00152048","phase":"PHASE4","title":"Evaluation of Eflornithine on Facial and Forearm Skin","status":"COMPLETED","sponsor":"Allergan","startDate":"2004-11-30","conditions":["Hirsutism"],"enrollment":78,"completionDate":"2005-10-31"},{"nctId":"NCT03767270","phase":"PHASE1,PHASE2","title":"Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency","status":"WITHDRAWN","sponsor":"Translate Bio, Inc.","startDate":"2019-12","conditions":["Ornithine Transcarbamylase Deficiency"],"enrollment":0,"completionDate":"2022-07"},{"nctId":"NCT00983580","phase":"PHASE2","title":"Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-08-20","conditions":["Adenomatous Polyp"],"enrollment":107,"completionDate":"2019-08-13"},{"nctId":"NCT03722641","phase":"NA","title":"Evaluation of Postprandial Glycaemia in a Healthy Population After Intake of Milk and Oat Based Products","status":"COMPLETED","sponsor":"Aventure AB","startDate":"2018-10-04","conditions":["Healthy"],"enrollment":20,"completionDate":"2019-03-05"},{"nctId":"NCT01548690","phase":"PHASE2","title":"Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury","status":"COMPLETED","sponsor":"William Lee","startDate":"2012-06","conditions":["Acute Liver Failure","Acute Liver Injury"],"enrollment":47,"completionDate":"2017-02-23"},{"nctId":"NCT00006079","phase":"PHASE2","title":"Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1998-06-19","conditions":["Cervical Cancer","Precancerous Condition"],"enrollment":150,"completionDate":"2004-04-27"},{"nctId":"NCT00021294","phase":"PHASE2","title":"Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2001-05","conditions":["Non-melanomatous Skin Cancer","Precancerous/Nonmalignant Condition"],"enrollment":0,"completionDate":"2002-06"},{"nctId":"NCT02158182","phase":"PHASE4","title":"Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding","status":"COMPLETED","sponsor":"Hospital General de Mexico","startDate":"2014-07","conditions":["Hepatic Encephalopathy"],"enrollment":88,"completionDate":"2016-06"},{"nctId":"NCT00006101","phase":"PHASE2","title":"Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer","status":"COMPLETED","sponsor":"Thomas E. Ahlering","startDate":"1998-10","conditions":["Prostate Cancer"],"enrollment":76,"completionDate":"2012-12"},{"nctId":"NCT01685827","phase":"PHASE2,PHASE3","title":"Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2012-10","conditions":["Human African Trypanosomiasis (HAT)","Sleeping Sickness"],"enrollment":394,"completionDate":"2017-04-26"},{"nctId":"NCT01912235","phase":"NA","title":"Arginine Synthesis in Healthy Adult Humans","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2007-09","conditions":["Healthy"],"enrollment":6,"completionDate":"2008-06"},{"nctId":"NCT00601640","phase":"PHASE2","title":"Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2007-01","conditions":["Other Benign Neoplasm of Skin, Unspecified"],"enrollment":184,"completionDate":"2014-12"},{"nctId":"NCT01722578","phase":"PHASE4","title":"L-ornithine L-aspartate in Overt Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Dayanand Medical College and Hospital","startDate":"2013-12","conditions":["Cirrhosis of Liver","Hepatic Encephalopathy"],"enrollment":200,"completionDate":"2017-01"},{"nctId":"NCT00216983","phase":"","title":"Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"1997-09","conditions":["Burns"],"enrollment":0,"completionDate":"2010-01"},{"nctId":"NCT00217035","phase":"","title":"Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"1997-08","conditions":["Burns"],"enrollment":0,"completionDate":"2010-01"},{"nctId":"NCT02820064","phase":"NA","title":"Effects of Hypoxia and Inflammation on Citrulline Synthesis by Ornithine Transcarbamylase in Human Enterocytes","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2016-01","conditions":["Hypoxia","Inflammation","Chronic Obstructive Pulmonary Disease"],"enrollment":30,"completionDate":"2017-01"},{"nctId":"NCT00146627","phase":"PHASE3","title":"Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"","conditions":["Trypanosomiasis, African"],"enrollment":280,"completionDate":"2008-06"},{"nctId":"NCT00718627","phase":"PHASE2","title":"Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders","status":"COMPLETED","sponsor":"Cytonet GmbH & Co. KG","startDate":"2008-07","conditions":["Urea Cycle Disorders","Carbamoylphosphate Synthetase I Deficiency","Ornithine Transcarbamylase Deficiency","Citrullinemia"],"enrollment":12,"completionDate":"2015-11"},{"nctId":"NCT01847651","phase":"PHASE4","title":"Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-08","conditions":["Hepatic Encephalopathy","Minimal Hepatic Encephalopathy","Cirrhosis"],"enrollment":42,"completionDate":"2015-06"},{"nctId":"NCT00472732","phase":"","title":"Neurologic Injuries in Adults With Urea Cycle Disorders","status":"COMPLETED","sponsor":"Andrea Gropman","startDate":"2007-03","conditions":["Brain Diseases, Metabolic, Inborn","Urea Cycle Disorder","Ornithine Transcarbamylase Deficiency"],"enrollment":46,"completionDate":"2010-07"},{"nctId":"NCT01624311","phase":"PHASE2","title":"Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants","status":"COMPLETED","sponsor":"Uta Lichter-Konecki","startDate":"2007-08","conditions":["Urea Cycle Disorders","Organic Acidemias"],"enrollment":5,"completionDate":"2015-05"},{"nctId":"NCT00305591","phase":"NA","title":"Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2006-03","conditions":["Cirrhosis","Hepatic Encephalopathy"],"enrollment":50,"completionDate":"2007-10"},{"nctId":"NCT01245816","phase":"PHASE3","title":"A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)","status":"WITHDRAWN","sponsor":"Cancer Prevention Pharmaceuticals, Inc.","startDate":"2011-03","conditions":["Familial Adenomatous Polyposis"],"enrollment":0,"completionDate":"2013-06"},{"nctId":"NCT00004498","phase":"PHASE1","title":"Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"1998-07","conditions":["Ornithine Transcarbamylase Deficiency Disease"],"enrollment":21,"completionDate":"2000-09"},{"nctId":"NCT01434108","phase":"PHASE2,PHASE3","title":"Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2011-10","conditions":["Gastrointestinal Bleeding","Cirrhosis"],"enrollment":48,"completionDate":"2015-03"},{"nctId":"NCT00118365","phase":"PHASE3","title":"Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1998-07","conditions":["Precancerous Condition"],"enrollment":375,"completionDate":"2008-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"NUI":"N0000006781","NDDF":"003541","UNII":"E524N2IXA3","CHEBI":"CHEBI:18257","VANDF":"4020565","INN_ID":"6167","RXNORM":"314709","UMLSCUI":"C0029277","chemblId":"CHEMBL446143","ChEMBL_ID":"CHEMBL446143","KEGG_DRUG":"D08302","DRUGBANK_ID":"DB00129","PDB_CHEM_ID":" ORN","PUBCHEM_CID":"6262","SNOMEDCT_US":"8514004","IUPHAR_LIGAND_ID":"725","MESH_DESCRIPTOR_UI":"D009952"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":19520,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 28","pmid":"41904136","title":"Structural basis for pH-responsive amino acid transport via SLC7A4.","journal":"Nature communications"},{"date":"2026 Mar 13","pmid":"41892305","title":"Role of Aspartate in Immune Response and Mortality in a Polymicrobial Sepsis Model: Insights from Metabolomics and Transcriptomics.","journal":"Cells"},{"date":"2026 Mar 26","pmid":"41887919","title":"Current Insight into Human Ornithine Aminotransferase: A Review.","journal":"Proteins"},{"date":"2026 Mar 25","pmid":"41880479","title":"Side Chain Length in Lysine and Its Homologues Modulates Noncovalent Interactions in Histidine-Rich Peptides.","journal":"The journal of physical chemistry. B"},{"date":"2026","pmid":"41878007","title":"Genetic constraints on protein loop evolution: out-of-frame stop codons limit Bacillus subtilis stationary-phase mutagenesis.","journal":"Frontiers in molecular biosciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:05.978000+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}